BNP Paribas Financial Markets Boosts Holdings in Henry Schein, Inc. (NASDAQ:HSIC)

BNP Paribas Financial Markets raised its position in Henry Schein, Inc. (NASDAQ:HSIC - Free Report) by 20.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 222,057 shares of the company's stock after purchasing an additional 37,575 shares during the quarter. BNP Paribas Financial Markets owned 0.18% of Henry Schein worth $15,366,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the company. Invesco Ltd. raised its holdings in shares of Henry Schein by 0.4% in the 4th quarter. Invesco Ltd. now owns 4,963,409 shares of the company's stock valued at $343,468,000 after buying an additional 17,552 shares during the period. FMR LLC grew its position in Henry Schein by 6.6% in the 4th quarter. FMR LLC now owns 3,498,033 shares of the company's stock valued at $242,064,000 after acquiring an additional 217,143 shares in the last quarter. Geode Capital Management LLC grew its position in Henry Schein by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 3,169,033 shares of the company's stock valued at $218,762,000 after acquiring an additional 14,876 shares in the last quarter. Palestra Capital Management LLC purchased a new stake in Henry Schein during the fourth quarter worth about $182,988,000. Finally, Fiduciary Management Inc. WI lifted its position in shares of Henry Schein by 7.2% during the fourth quarter. Fiduciary Management Inc. WI now owns 2,488,335 shares of the company's stock worth $172,193,000 after purchasing an additional 167,990 shares in the last quarter. 96.62% of the stock is currently owned by institutional investors and hedge funds.

Henry Schein Stock Down 0.7%

Shares of NASDAQ HSIC traded down $0.46 during midday trading on Wednesday, hitting $70.08. 1,568,384 shares of the company's stock were exchanged, compared to its average volume of 1,640,455. The firm's fifty day simple moving average is $67.52 and its 200-day simple moving average is $71.45. The company has a market cap of $8.53 billion, a PE ratio of 28.84, a P/E/G ratio of 2.13 and a beta of 0.87. Henry Schein, Inc. has a twelve month low of $60.56 and a twelve month high of $82.49. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82.

Henry Schein (NASDAQ:HSIC - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $1.11 by $0.04. Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The business had revenue of $3.17 billion for the quarter, compared to analysts' expectations of $3.24 billion. During the same period in the previous year, the company posted $1.10 EPS. The company's quarterly revenue was down .1% on a year-over-year basis. Research analysts predict that Henry Schein, Inc. will post 4.74 EPS for the current fiscal year.

Insider Buying and Selling

In other Henry Schein news, CEO Bradford C. Connett sold 4,036 shares of the stock in a transaction that occurred on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total transaction of $287,161.40. Following the completion of the sale, the chief executive officer now directly owns 62,688 shares of the company's stock, valued at approximately $4,460,251.20. This trade represents a 6.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Philip A. Laskawy sold 2,604 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the transaction, the director now directly owns 24,805 shares in the company, valued at approximately $1,762,147.20. The trade was a 9.50% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.08% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on HSIC shares. Jefferies Financial Group raised their price objective on shares of Henry Schein from $77.00 to $80.00 and gave the company a "hold" rating in a research note on Thursday, January 23rd. UBS Group dropped their price target on shares of Henry Schein from $83.00 to $80.00 and set a "neutral" rating for the company in a research note on Wednesday, February 26th. Piper Sandler cut their price objective on Henry Schein from $83.00 to $77.00 and set an "overweight" rating on the stock in a research report on Wednesday, April 30th. Barrington Research cut their price objective on Henry Schein from $90.00 to $86.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Finally, StockNews.com lowered Henry Schein from a "buy" rating to a "hold" rating in a research report on Thursday, April 17th. Six research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $79.30.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.